Skip to main content
Premium Trial:

Request an Annual Quote

IDBS Providing Data Management Tool to Genomic Health

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – IDBS today said it will provide tools to Genomic Health for its new clinical research data management and decision-capture platform.

Financial terms of the agreement were not disclosed.

Genomic Health develops oncology molecular diagnostics using gene expression technologies, and has two clinically validated assays for breast cancer and colon cancer. As the company generates increasing amounts of data, IDBS' tools will help Genomic Health capture genomic data from the platforms and enable scientists to query the data across multiple experiments, Guildford, UK-based IDBS said in a statement.

The tools will also provide Genomic Health researchers easy access to necessary data to run experiments and ensure that all intellectual property is "effectively captured at the point of invention."

"As we have expanded and refined our assays, the amount and heterogeneity of data generated has increased significantly, and the IDBS platform will help us manage the data today and as our organization continues to grow in the future," said Joel Robertson, senior manager of LIMS software for Genomic Health.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.